Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

doi:10.3748/wjg.v13.i48.6553

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 48

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1917)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-4) series.

Item

Count

PDF

210

HTML

1591

Tables (1-4)

116

Sum=1917

Dec 28, 2007 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Dec 28, 2007; 13(48): 6553-6557
Published online Dec 28, 2007. doi: 10.3748/wjg.v13.i48.6553

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Giuseppe Di Lorenzo, Antonio Rea, Chiara Carlomagno, Stefano Pepe, Giovannella Palmieri, Roberto Labianca, Antonio Chirianni, Alfonso De Stefano, Vincenzo Esposito, Sabino De Placido, Vincenzo Montesarchio

Giuseppe Di Lorenzo, Chiara Carlomagno, Stefano Pepe, Giovannella Palmieri, Alfonso De Stefano, Sabino De Placido, Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, Naples, Italy

Antonio Rea, Vincenzo Montesarchio, Divisione di Oncologia, Azienda Ospedaliera Cotugno, Naples, Italy

Antonio Chirianni, Vincenzo Esposito, Divisione di Malattie Infettive Azienda Ospedaliera, Cotugno, Napoli, Italy

Roberto Labianca, Oncology Section, Ospedali Riuniti, Bergamo, Italy

Correspondence to: Giuseppe Di Lorenzo, MD, PhD, Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, Naples, Italy. giuseppedilorenzoncol@hotmail.com

Telephone: +39-81-7462053 Fax: +39-81-7463660

Received: July 17, 2007
Revised: August 6, 2007
Accepted: August 16, 2007
Published online: December 28, 2007

Core Tip